Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

38.47 +0.74 (+1.95%)
Streaming Delayed Price Updated: 11:59 AM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 293,947
Open 37.73
Bid (Size) 38.38 (100)
Ask (Size) 38.48 (300)
Prev. Close 37.73
Today's Range 37.73 - 38.77
52wk Range 14.62 - 49.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
From Definium Therapeutics, Inc.
Via Business Wire

Performance

YTD
+150.1%
+150.1%
1 Month
-6.0%
-6.0%
3 Month
+59.5%
+59.5%
6 Month
+113.9%
+113.9%
1 Year
+150.1%
+150.1%

More News

Read More
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge ↗
Via Chartmill
News headline image
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study ↗
Via MarketBeat
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
From USA News Group
Via GlobeNewswire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics, Inc. Announces Proposed Public Offering
From Definium Therapeutics, Inc.
Via Business Wire
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
Via Chartmill
Which stocks are moving on Monday? ↗
Via Chartmill

Frequently Asked Questions

Is Definium Therapeutics, Inc. - Common Shares publicly traded?
Yes, Definium Therapeutics, Inc. - Common Shares is publicly traded.
What exchange does Definium Therapeutics, Inc. - Common Shares trade on?
Definium Therapeutics, Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Definium Therapeutics, Inc. - Common Shares?
The ticker symbol for Definium Therapeutics, Inc. - Common Shares is DFTX on the Nasdaq Stock Market
What is the current price of Definium Therapeutics, Inc. - Common Shares?
The current price of Definium Therapeutics, Inc. - Common Shares is 38.47
When was Definium Therapeutics, Inc. - Common Shares last traded?
The last trade of Definium Therapeutics, Inc. - Common Shares was at 09/11/26 11:59 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.